25. Ng LG, Hsu A, Mandell MA, Roediger B, Hoeller C, et al. (2008) Migratory Dermal Dendritic Cells Act as Rapid Sensors of Protozoan Parasites. Plos Pathog 4: e1000222. 26. Reed ML, Lye WK (2004) Microsystems for Drug and Gene Delivery. Proc IEEE 92: 56–75. 27. Fernando GJP, Stewart TJ, Tindle RW, Frazer IH (1998) Th2-type CD4(+) cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol 161: 2421–2427. 28. Noah DL, Hill H, Hines D, White EL, Wolff MC (2009) Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure. Clin Vaccine Immunol 16: 558–566. 29. Hobson D, Curry RL, Beare AS, Wardgard A (1972) A Role of serum hemagglutination-in hibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hygiene 70: 767–777. 30. Food & Drug Administration (2007) Guidance for industry: clinical data needed to support for licensure of seasonal inactivated influenza vaccines. http://www. fda.gov/cber/gdlns/trifluvac.htm#iii). 31. Coulter A, Wong TY, Drane D, Bates J, Macfarlan R, Cox J (1998) Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms (TM)) and oil-in-water vaccines. Vaccine 16: 1243–1253. 32. Friedmann PS (1981) Disapperance of epidermal Langerhans cells during puva therapy. Brit J Dermatol 105: 219–221. 33. Falstiejensen N, Spaun E, Brochnermortensen J, Falstiejensen S (1988) The influence of epidermal thickness on thans-cutaneous oxygen-pressure measure- ment in normal persons. Scand J Clin Lab Inv 48: 519–523. Skin Targeted Vaccinations 34. Frolov VG, Seid RC, Odutayo O, Al-Khalili M, Yu JM, et al. (2008) Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch. Influenza Other Respi. Viruses 2: 53–60. 35. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5: 905–916. 36. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77: 789–800. 37. Chen X, Prow TW, Crichton ML, Jenkins DWK, Roberts MS, et al. (2009) Dry- coated microprojection array patches for targeted delivery of immunotherapeu- tics to the skin. J Control Rel 139: 212–220. 38. Crichton ML, Ansaldo A, Chen X, Prow TW, Fernando GJP, et al. (2010) The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials;Doi: 10.1016/ j.biomaterials.2010.02.022. 39. U.S. Food and Drug Administration. Available: http://www.accessdata.fda.gov/ scripts/cder/iig/getiigWEB.cfm. 40. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, et al. (1999) Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17: 2826–2829. 41. Kols A, Sherris J, HPV vaccines: promise and challenges. Available: http:// www.path.org/files/jsrp13710.pdf. 42. Fernando GJP, Stenzel DJ, Tindle RW, Merza MS, Morein B, et al. (1995) Peptide polymerization facilitates incorporation iscoms and increases antigen- specific IgG2a production. Vaccine 13: 1460–1467. 43. Fazekas de St Groth S, Webster RG (1966) Disquisitions on original antigenic sin. 1. Evidence in man. J Exp Med 124: 331. PLoS ONE | www.plosone.org 11 April 2010 | Volume 5 | Issue 4 | e10266